

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the  
Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): June 29, 2020**

**OBALON THERAPEUTICS, INC.**

(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction of incorporation)

**001-37897**

(Commission  
File Number)

**20-1828101**

(IRS Employer  
Identification No.)

**5421 Avenida Encinas, Suite F  
Carlsbad, California**

(Address of principal executive offices)

**92008**

(Zip Code)

**(844) 362-2566**

(Registrant's telephone number, including area code)

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common stock, par value \$0.001 per share	OBLN	The NASDAQ Stock Market LLC (NASDAQ Global Market)

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 5.08 Shareholder Director Nominations.**

On June 29, 2020, the Board of Directors of Obalon Therapeutics, Inc. ("the Company") established that the Company's 2020 Annual Meeting of Stockholders (the "2020 Annual Meeting") will be held virtually by means of remote communication on Wednesday, September 16, 2020. The record date for the determination of stockholders of the Company entitled to receive notice of and to vote at the 2020 Annual Meeting shall be the close of business on Tuesday, July 28, 2020. Because the date of the 2020 Annual Meeting differs by more than thirty days from the anniversary date of the 2019 Annual Meeting of Stockholders, which was held on July 23, 2019, the deadlines for any stockholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the "Exchange Act"), are no longer applicable. Pursuant to Rule 14a-5(f) of the Exchange Act, the Company is hereby providing notice of the revised deadline for such proposals by means of this Form 8-K.

Any stockholder proposal intended to be considered for inclusion in the Company's proxy materials for the 2020 Annual Meeting in accordance with Rule 14a-8 must be delivered to, or mailed to and received at, the Company's principal executive offices at 5421 Avenida Encinas, Suite F, Carlsbad, California 92008, Attention: Corporate Secretary, on or before the close of business on July 6, 2020, which the Company has determined to be a reasonable time before it expects to begin to print and distribute its proxy materials prior to the 2020 Annual Meeting. In addition to complying with this deadline, stockholder proposals intended to be considered for inclusion in the Company's proxy materials for the 2020 Annual Meeting must also comply with all applicable Securities and Exchange Commission rules, including Rule 14a-8.

**Item 8.01 Other Events.**

In connection with recent leadership changes at the Company, on June 29, 2020, the Company's Board of Directors appointed Kim Kamdar, an independent director, as Chairperson of the Board of Directors. Ms. Kamdar assumes the role previously held by Andrew Rasdal, who was recently appointed President and Chief Executive Officer of the Company. Mr. Rasdal will continue to serve as a director of the Company.

**SIGNATURE**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**OBALON THERAPEUTICS, INC.**

Date: June 30, 2020

By: /s/ Nooshin Hussainy

Nooshin Hussainy

Chief Financial Officer